Clovis Oncology (CLVS) Tops Q1 EPS by 22c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. RXRX

Go back to Clovis Oncology (CLVS) Tops Q1 EPS by 22c

Clovis Oncology Announces Q1 2016 Operating Results and Corporate Update

May 5, 2016 4:08 PM EDT

Rucaparib rolling NDA submission initiated for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors and expected to complete Q2 2016 Rucaparib MAA submission planned Q4 2016 Clovis preparing for potential U.S. commercial launch of rucaparib with existing commercial infrastructure in Q4 2016 or Q1 2017 ARIEL3 pivotal rucaparib maintenance study target enrollment completed Clovis entered into a clinical trial collaboration to evaluate a novel combination therapy of atezolizumab (MPDL3280A; anti-PDL1) and rucaparib for the treatment of gynecological cancers... More